Allied Corp. Strengthens Board of Directors With Appointment of Seasoned Biopharmaceutical Executive Mr. Jim Smeeding

KELOWNA, British Columbia, May 08, 2020 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the "Company") (OTCQB: ALID), an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues is pleased to announce the appointment of Jim Smeeding, RPh, MBA, to the Company’s Board of Directors. In addition to this, Mr. Smeeding will also work within the management team and fulfil the role of Vice President of Pharmaceuticals.

Jim Smeeding is a Registered Pharmacist (RPh) from the State University of New York, and also holds a Masters degree in Business Administration (MBA) from the University of Texas (with an emphasis in pharmaceutical marketing, organizational strategies and pharma sales management). He is the Executive Vice President of CP Pharmaceutical International: a division of CP Global Health (Hong Kong and Texas).

Some of Mr. Smeeding’s past experience has included working as the Executive Director of the National Association of Specialty Pharmacy (NASP), a founder of the Center for Pharmacoeconomic Studies at the University of Texas College of Pharmacy and a founder and President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).

Within Mr. Smeeding’s specialty pharmacy consultancy practice, Project Rx, Mr. Smeeding has offered management services to hospitals and pharmaceutical companies throughout the US. Mr. Smeeding has also been active in other Cannabis Based Medicines (CBM) research as a founder of CannaPharma Rx and has authored more than 85 peer-reviewed publications and has given hundreds of presentations.

Mr. Smeeding has worked with many major pharmaceutical companies and is one of the founding partners and president of Indication Biosciences; an early stage drug discovery company that is examining the use of CBD with statin agents to safely lower lipid anomalies. Mr. Smeeding also was the Executive VP and founder of Engaged Media; a technology driven patient engagement solution used in multiple pharmaceutical co-pay programs that was acquired in May of 2018.

As President of the National Payer Roundtable, Mr. Smeeding is in regular contact with the Chief Medical Officers and Chief Pharmacy Officers of national and regional health insurers, as well as, pharmaceutical executives.

"As a seasoned entrepreneur working with companies and organizations focused on cannabis-based medicines, we are delighted that Jim is bringing his pharmaceutical insight and commercial expertise to our board as we continue to make progress with our pharmaceutical product development. We look forward to Jim's expert leadership in guiding our objectives to bring Allied’s pharma products towards commercialization,” said Calum Hughes, CEO of Allied. "Jim is a very highly regarded and experienced medical cannabis and pharmaceutical expert. His network within the Pharma industry will present many advantages to Allied regarding research and development, commercialization and licensing of our pharma products.”